Innovation + Divide...
Health Care: Drugs
Oragenics Inc. (ORNI: OTC)
$1.15 0.00 | 0.00%
02/09/12 - 11:48 AM ET
1.53K / 1.10K
Vol / Avg. Vol:1.10 / 1.15
Open / Prev. Close:1.10 - 1.15
Today's Range:0.75 - 6.50
52 Wk Range:13.86%
Performance YTD:TheStreet Rating:
Portfolios with ORNI
- Portfolio NameUser Type
Latest ORNI Headlines from TheStreet
- Director Nelson Peltz Buys $15.9M More of Legg Mason 01.05.10 | 09:01 am
Press Releases for ORNI
- Oragenics, Inc. Announces Advisory Relationship With Dr. Richard Nagelberg, DDS - Business Wire 02.09.12 | 08:02 am
- Oragenics, Inc. Announces Appointment Of Michael Sullivan As Chief Financial Officer - Business Wire 02.02.12 | 08:02 am
- Oragenics Announces Fifth Amendment To Unsecured Revolving Line Of Credit To Provide $750,000 Of Additional Funding - Business Wire 01.25.12 | 11:01 am
- Oragenics, Inc., A Leader In Oral Care Probiotics Presents Strategic Update At Biotech Showcase™ 2012 In San Francisco - Business Wire 01.11.12 | 10:01 am
- Oragenics Highlights Strategic Direction For 2012 In Corporate Video - Business Wire 01.05.12 | 08:01 am
- Oragenics Announces Fourth Amendment To Unsecured Revolving Line Of Credit To Provide $500,000 Of Additional Funding - Business Wire 12.14.11 | 08:12 am
- Oragenics Promotes Senior Management Team To Accommodate Scientific Research And Operations Expansion Plan - Business Wire 12.06.11 | 08:12 am
- Oragenics Announces Retirement Of Dr. Jeffrey Hillman - Business Wire 10.14.11 | 04:10 pm
- Oragenics, Inc. Receives U.S. Patent For IVIAT Platform Technology - Business Wire 10.12.11 | 09:10 am
- Frost & Sullivan Recognizes Oragenics For Its Unique ProBiora3® That Promotes Oral Health For Both Humans And Companion Animals - Business Wire 10.04.11 | 04:10 pm
Partner Headlines for ORNI
